z-logo
open-access-imgOpen Access
Safety, Pharmacokinetics, and Pharmacodynamics of ASP 3662, a Novel 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Healthy Young and Elderly Subjects
Author(s) -
Bellaire Susan,
Walzer Mark,
Wang Tianli,
Krauwinkel Walter,
Yuan Nancy,
Marek Gerard J.
Publication year - 2019
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12618
Subject(s) - pharmacokinetics , pharmacodynamics , tolerability , pharmacology , medicine , adverse effect
Inhibition of the enzyme 11 β ‐hydroxysteroid dehydrogenase type 1 (11β‐ HSD 1) represents a potential mechanism for improving pain conditions. ASP 3662 is a potent and selective inhibitor of 11β‐ HSD 1. Two phase I clinical studies were conducted to assess the safety, tolerability, pharmacokinetics ( PK s), and pharmacodynamics (PDs) of single and multiple ascending doses of ASP 3662 in healthy young and elderly non‐Japanese and young Japanese subjects. Nonlinear, more than dose‐proportional PK s were observed for ASP 3662 after single‐dose administration, particularly at lower doses (≤ 6 mg); the PK s at steady state were dose proportional, although the time to ASP 3662 steady state was dose dependent at lower doses (≤ 2 mg). Similar PK s were observed among young Japanese, young non‐Japanese, and elderly non‐Japanese subjects. Specific inhibition of 11β‐ HSD 1 occurred after both single and multiple doses of ASP 3662. A marked dissociation between PKs and PDs was observed after single but not multiple doses of ASP 3662. ASP 3662 was generally safe and well tolerated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here